<DOC>
	<DOC>NCT02077335</DOC>
	<brief_summary>The purpose of this study is to determine the clinical efficacy and toxicity of High-dose rate (HDR) brachytherapy as monotherapy for the treatment of low risk and intermediate risk prostate cancer.</brief_summary>
	<brief_title>Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Biopsy proven Adenocarcinoma of the Prostate Clinical stage T1c, T2a or T2b PSA less than 20 ng/ml Gleason Score 6 or 7 Age less than 18 years Clinical stage T2c, T3 ou T4 Clinical Stage N1 Clinical Stage M1 Prostate Specific Antigen (PSA) more than 20 ng/ml Gleason score 8 or higher IPSS score 19 or higher with alphablockers Past radiation therapy to the pelvis History of Collagen Vascular Disease History of Inflammatory Bowel Disease Bilateral Hip Prosthesis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Brachytherapy</keyword>
	<keyword>Monotherapy</keyword>
	<keyword>HDR</keyword>
</DOC>